FDA approves Otsuka’s ADHD drug Simtriyo, teeing up its ‘next major CNS launch’
9 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"FDA approves Otsuka’s ADHD drug Simtriyo, teeing up its ‘next major CNS launch’" is generating significant coverage in the Business category, with 10 articles from 9 distinct sources tracked by PULSE so far.
Outlets currently covering the story include BioWorld News, Managed Healthcare Executive, Medscape and MedPage Today. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 108d ago.
Quick answers
Why is "FDA approves Otsuka’s ADHD drug Simtriyo, teeing up its ‘next major CNS launch’" trending?
Because 9 independent news sources published 10 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (10)
- Otsuka’s Simtriyo nod: Qelbree vs. three in ADHD? BioWorld News · 111d ago
- FDA approves Simtriyo, the first triple reuptake inhibitor for ADHD Managed Healthcare Executive · 111d ago
- FDA Approves First NDSRI for ADHD in Adults and Children Medscape · 111d ago
- First-in-Class Drug for ADHD Wins FDA Approval MedPage Today · 111d ago
- Otsuka’s Simtriyo nod: Qelbree vs. three in ADHD? BioWorld News · 111d ago
- FDA Approves Simtriyo Pharmaceutical Executive · 111d ago
- Otsuka's triple reuptake inhibitor Simtriyo wins FDA OK for ADHD FirstWord Pharma · 111d ago
- Otsuka’s ADHD approval opens up new drug class with $615M opportunity BioSpace · 111d ago
- FDA Approves Centanafadine for ADHD in Children, Adolescents, and Adults Psychiatric Times · 111d ago
- FDA approves Otsuka’s ADHD drug Simtriyo, teeing up its ‘next major CNS launch’ Fierce Pharma · 111d ago
Topics
Related trends
FDA rejects Summit’s ivonescimab, derailing US arrival of much-hyped PD-1xVEGF class
The United States Food and Drug Administration has rejected Summit Therapeutics and Akeso's lung cancer drug ivonescimab.
Common ADHD classroom accommodations may not help students succeed, study finds
New research questions the effectiveness of standard classroom accommodations for students diagnosed with ADHD.
EXCLUSIVE: US FDA shelves commissioner's voucher program for speedy drug reviews, sources say
The US FDA has shelved its commissioner's priority review voucher pilot program for expedited drug reviews, according to exclusive reporting from Reuters and coverage across multiple outlets.
Christina Applegate fears that ‘poisoning’ may be behind her misdiagnosis of MS
Christina Applegate reveals she is investigating whether breast implant illness caused her multiple sclerosis misdiagnosis, calling it potential 'poisoning.'
FDA orders new warning labels on Ozempic, Wegovy over rare risk of permanent vision loss
Federal regulators mandate new vision loss warning labels across the widely used GLP-1 receptor agonist drug class.
FDA tells GLP-1 makers to warn of potential vision loss side effect
The FDA is requiring all GLP-1 drug makers to add warnings about a possible increased risk of NAION, a rare eye condition that can cause sudden and permanent vision loss.